<p style="text-align: justify;">.</p> <h2>NON-RECEPTOR TYROSINE KINASE INHIBITORS</h2> <h3>1. Bcr-Abl1 Inhibitors</h3> <h3>2. JAK Inhibitors</h3> <h3>3. BTK Inhibitors</h3> <h3><u>Check Also</u></h3> <h4>KINASE INHIBITORS - An Overview</h4> <h4>RECEPTOR TYROSINE KINASE INHIBITORS</h4> <section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="92263f8" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;"><a href="https://insights.omicsx.com/receptor-tyrosine-kinase/">1. Anaplastic Lymphoma Kinase (ALK) inhibitors</a></h5></section><section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="3d711ab" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;"><a href="https://insights.omicsx.com/receptor-tyrosine-kinase/">2. c-Met inhibitors</a></h5></section><section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="bf4d132" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;">3. EGFR Inhibitors</h5></section><section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="d76fe1d" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;">4. FLT3 Inhibitors</h5></section><section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="11eb0d3" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;">5. VEGFR/FGFR/PDGFR Inhibitors</h5></section><section style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Lato, Helvetica, Arial, sans-serif; --flex-direction: initial; --flex-wrap: initial; --justify-content: initial; --align-items: initial; --align-content: initial; --gap: initial; --flex-basis: initial; --flex-grow: initial; --flex-shrink: initial; --order: initial; --align-self: initial; flex-direction: var(--flex-direction); flex-wrap: var(--flex-wrap); -webkit-box-pack: var(--justify-content); justify-content: var(--justify-content); -webkit-box-align: var(--align-items); align-items: var(--align-items); align-content: var(--align-content); gap: var(--gap); flex-basis: var(--flex-basis); -webkit-box-flex: var(--flex-grow); flex-grow: var(--flex-grow); flex-shrink: var(--flex-shrink); -webkit-box-ordinal-group: var(--order); order: var(--order); align-self: var(--align-self); --widgets-spacing: 20px; color: #333333;" data-id="10994f6" data-element_type="section"><h5 style="font-weight: var( --e-global-typography-primary-font-weight ); font-family: var( --e-global-typography-primary-font-family ), Sans-serif;">6. TRK Inhibitors</h5></section> <h4>SERINE / THEONINE KINASE INHIBITORS</h4> <section data-id="89790ad" data-element_type="section"> <h5>1. BRAF/MEK/ERK Inhibitors</h5> </section><section data-id="47f0ede" data-element_type="section"> <h5>2. CDK Inhibitors</h5> </section><section data-id="5e43c0f" data-element_type="section"> <h5>3. PI3K/AKT/mTOR Inhibitors</h5> </section><ul><li><b>Kinase Inhibitors - An Overview</b></li><li><a href="https://insights.omicsx.com/approved-cancer-kinase-inhibitors/"><strong>Approved</strong> Oncology Targeting Kinase Inhibitors. (8<i style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Roboto, sans-serif;">6 Molecules)</i></a></li><li><a href="https://insights.omicsx.com/approved-non-oncology-small-molecule-kinase-inhibitors/">Approved Non-Oncology Targeting Kinase Inhibitors. (1<i style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Roboto, sans-serif;">6 Molecules)</i></a></li><li><a href="https://insights.omicsx.com/oncology-clinical-stage-kinase-inhibitors/"><strong>Kinase Inhibitors </strong>in <em>Active Clinical Development</em> - Developers, Pipeline, Target & Cancer Indication. (330 Molecules)</a></li><li><a href="https://insights.omicsx.com/oncology-preclinical-stage-kinase-inhibitors/"><strong>Kinase Inhibitors</strong> in <em>Active Preclinical Development</em> - Developers, Pipeline, Target & Cancer Indication. (<i>244 Molecules)</i></a></li><li><a href="https://insights.omicsx.com/kinase-clinical-drug-developers/"><b>Clinical Stage Companies Developing </b>Oncology Targeting Kinase Inhibitors. (227<i style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Roboto, sans-serif;"> Companies)</i></a></li><li><a href="https://insights.omicsx.com/small-molecule-kinase-preclinical-drug-developers/">Preclinical / Early Stage Companies Developing Oncology Targeting Kinase Inhibitors. (122<i style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; font-size: 16px; font-family: Roboto, sans-serif;"> Companies)</i></a></li></ul>